

15th May 2020

Dear Therapeutic Goods Act Scheduling Committee,

I write this letter of support for the removal of CBD (Cannabidiol) from schedule 4 of the TGA to be regulated as a complimentary medicine.

I personally suffer chronic pain and Osteoporosis, and am currently prescribed medicinal Cannabis with a 10% THC (Tetrahydrocannabinol) and 10% CBD (Cannabidiol) ratio. The accessibility, and supply by manufacturer, as too the cost of this medication is, at times, quite distressing. However, the process legitimises the use, and removes harmful stigma that is attached to Cannabis Marijuana.

Alternatively, Cannabis Hemp based CBD, does not include THC (which is the psychotropic component of marijuana), and has higher CBD content over Marijuana genus of Cannabis. Therefore, CBD does not contain a psychotropic component. CBD supports the newly discovered Endocannabinoid system. The Endocannabinoid system regulates homeostasis of the body and other autoimmune disorders.

I supplement my medicinal cannabis with CBD paste, to add further relief from symptoms that I experience daily. The process of purchase is convoluted and quality and consistency of product can be considered. As too, the purchase of such complimentary medicine requires prescription. The procedure of obtaining prescriptions for such medications is a drawn-out process through interviews and approval requests, prior to prescriptions issued. These processes continue with each new script.

To address the TGA 1989 – Sect 52E

(http://www5.austlii.edu.au/au/legis/cth/consol_act/tga1989191/s52e.html) accessed 15-5-20.

1 (a): There is limited risk with CBD use, no reports of serious side effects. CBD supports lowering symptoms of anxiety, which I experienced with chronic pain and Opiate medication.

CBD supported my Opiate and Benzodiazepine withdrawal.

(b): CBD can be used as a complimentary medicine, as used for my chronic pain management. It is a supplementary support for the Endocannabinoid system that assists the autoimmune system and regulates homeostasis balance of the body.

(c): CBD from cannabis marijuana is isolated from THC, being the psychotropic component of cannabis marijuana. CBD from cannabis Hemp, contains no THC in the plant, pure CBD only is extracted. Both forms of Cannabis CBD do not contain a psychotropic component.

(d): Manufacturing opportunities for CBD will standardise quality, chemical ratios, and reduce current cost. Labelling as per government requirements.

(e): CBD has no potential for abuse. Its effects are similar to having a relaxing Beer, although unlike alcohol, increased amounts will not increase effects. The body takes its own required need and expels the rest. Its anti-anxiety effect is very supportive.

(f): Follow dosage as per consulted.

I fully endorse the removal of CBD (Cannabidiol) from schedule 4 of the TGA to be regulated as a complimentary medicine.

Kind regards,